0 CHECKOUT

2016 Analysis of Transfusion Diagnostic Assays, and Strategic Profiles of Leading Suppliers

  • ID: 3494535
  • November 2015
  • 280 pages
  • VPG Market Research
1 of 3

FEATURED COMPANIES

  • Abbott
  • Biokit
  • Competitive Assessments
  • Fujirebio
  • Immucor
  • Quest
  • MORE

This 280-page report presents a comprehensive analysis of the clinical significance and market needs for major blood typing, grouping, and infectious disease screening assays, including NAT tests, as well as extensive listings of companies developing or marketing new blood banking technologies and products.

The report also presents strategic assessments of current and emerging suppliers, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Contains 280 pages and 6 tables

Note: Product cover images may vary from those shown
2 of 3

Competitive Assessments

- Abbott
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- BioMerieux
- Bio-Rad
- CellMark Forensics/LabCorp
- Diagast
- DiaSorin
- Fujirebio
- Grifols
- Hologic/Gen-Probe
- Immucor
- Ortho-Clinical Diagnostic
- Proteome Sciences
- Quest
- Quidel
- Roche
- Siemens
- Tecan
- Thermo Fisher/Life Technologies

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Stanford Blood Center
  • Sanquin
  • Canadian Blood Services
  • Bloodworks Northwest
  • The Blood Center
  • Oneblood Inc.